So ACHN, prior to its after-hours drop, has a market cap of $800M+. Like INO, it's still in development stages with no revenues. I only show a Phase II trial completed, one other in stage other than a few other initial trial studies. How is INO only valued at $160M then? Granted you might say ACHN is just further along with its trials but still nothing proven. Is it just a matter of time then for INO?